Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

ConcertAI integrates with imaging technology specialist TeraRecon

By Brian Buntz | November 16, 2021

Terarecon-ConcertAIPrivately-held ConcertAI has formally integrated with TeraRecon, a provider of advanced visualization services, including 3D and 4D medical imaging post-processing. 

Cambridge, Massachusetts–based ConcertAI says the integration will expand its offerings for life science companies, which now can integrate data from electronic medical records, genomic data and medical imaging. As a result, the company can offer software-as-a-service (SaaS) clinical research and clinical decision support applications. 

“For oncology studies, imaging is a critical part of both patient care and defining response to therapy,” said Kenneth G. Faulkner, SVP of clinical trial solutions at ConcertAI. In 2018, the FDA released guidance on the use of imaging in clinical trials highlighting the need for standardized procedures to “reduce variability and to ensure interpretability of the results.”

Kenneth G. Faulkner

Kenneth G. Faulkner

“While the clinical use of imaging is somewhat standardized for patient care, clinical studies — particularly in oncology — require trial-specific standards for accurate endpoint determination,” Faulkner said.

TeraRecon is currently in use in 1,300 clinical sites internationally. 

TeraRecon is a segment winner in advanced visualization, according to KLAS Research, a market research firm.  

ConcertAI plans on integrating TeraRecon’s technologies into its Digital Clinical Trials Network. 

“TeraRecon provides the necessary analytic tools and procedures for standardizing imaging endpoints in oncology,” Faulkner said. “By deploying TeraRecon tools into ConcertAI workflows, we can better control standardized workflows and assessments within the clinical trial setting — leading to more accurate assessments of disease progression and treatment efficacy.”

In 2021, ConcertAI has announced a string of collaborations related to pharmaceutical clinical trials, including an expanded data science partnership with Janssen (NYSE:JNJ), Novartis (NYSE:NVS) and Syneos Health (NSDQ:SYNH). 


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: AI-augmented diagnosis, ConcertAI, Digital Clinical Trials Network, Janssen, medical imaging post-processing, Novartis, Syneos Health, TeraRecon
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50